Source: Eur Respir J, 49 (5) 1700407; 10.1183/13993003.00407-2017
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Stéphane Jouneau, Alice Ballerie, Mallorie Kerjouan, Xavier Demant, Elodie Blanchard, Mathieu Lederlin. Haemodynamically proven pulmonary hypertension in a patient with GATA2 deficiency-associated pulmonary alveolar proteinosis and fibrosis. Eur Respir J, 49 (5) 1700407; 10.1183/13993003.00407-2017

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary alveolar proteinosis and idiopathic pulmonary hemosiderosis Source: International Congress 2019 – CCC Airway diseases Year: 2019 Association of pulmonary alveolar proteinosis and fibrosis: patient with GATA2 deficiency Source: Eur Respir J 2016; 48: 1510-1514 Year: 2016 Pulmonary hypertension in patients with idiopathic pulmonary fibrosis Source: Eur Respir Mon 2012; 57: 148-160 Year: 2012 The impact of emphysema in pulmonary fibrosis Source: Eur Respir Rev 2013; 22: 153-157 Year: 2013 Pulmonary hypertension in patients with idiopathic pulmonary fibrosis and combined pulmonary fibrosis and emphysema: hemodynamic severity Source: International Congress 2018 – Pulmonary hypertension in lung diseases and the role of the right ventricle Year: 2018 Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity Source: Eur Respir J 2005; 26: 586-593 Year: 2005 Pulmonary hypertension in idiopathic pulmonary fibrosis Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis Year: 2010 Diffuse pulmonary fibrosis and pulmonary emphysema associated with paradoxically normal spirometry Source: Eur Respir J 2006; 28: Suppl. 50, 100s Year: 2006 Our cases with pulmonary alveolar proteinosis Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs) Year: 2018 Subtypes of pulmonary emphysema on HRCT affect prognosis on combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 The role of apoptosis in idiopathic pulmonary alveolar proteinosis Source: Annual Congress 2006 - Usefulness of broncoalveolar lavage (BAL) in interstitial lung diseases Year: 2006 Pulmonary arterial hypertension in combined pulmonary emphysema and fibrosis Source: Annual Congress 2005 - Pulmonary arterial hypertension diagnosis and therapy Year: 2005 Occult alveolar haemorrhage in pulmonary veno-occlusive disease Source: Eur Respir J 2006; 27: 108-113 Year: 2006 Abnormal pulmonary arterial remodelling in patients with combined pulmonary fibrosis emphysema (CPFE) and idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2011 - Clinical approach of diffuse parenchymal lung disease Year: 2011 Coexistent pulmonary emphysema delays the decrease in vital capacity in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease Year: 2008 Pulmonary vascular changes in COPD and idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2006 - Clinical physiology Year: 2006 VEGF expression does not differentiate between idiopathic pulmonary fibrosis and pulmonary sarcoidosis Source: Eur Respir J 2007; 30: Suppl. 51, 574s Year: 2007 Pulmonary hypertension is common in end-stage sarcoidosis Source: Annual Congress 2005 - Progresses in granolomatous lung disease Year: 2005 Titrated oxygen requirement and prognostication in idiopathic pulmonary fibrosis Source: Eur Respir J 2012; 39: 359-365 Year: 2012